Arcus Biosciences Inc (RCUS) — Cash Flow-to-Debt Ratio
Arcus Biosciences Inc (RCUS) has a Cash Flow-to-Debt Ratio of -0.29x as of March 2026, meaning its operating cash flow of $-138.00 Million could theoretically repay 0% of its total liabilities ($473.00 Million) in one year. See Arcus Biosciences Inc (RCUS) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arcus Biosciences Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Arcus Biosciences Inc across 10 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Arcus Biosciences Inc.
Annual Cash Flow-to-Debt Ratio for Arcus Biosciences Inc (2016–2025)
Year-by-year debt coverage analysis for Arcus Biosciences Inc. Check Arcus Biosciences Inc (RCUS) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.95x | $-482.00 Million | $508.00 Million | ▼ -271.2% |
| 2024 | -0.26x | $-170.00 Million | $665.00 Million | ▲ +47.1% |
| 2023 | -0.48x | $-306.00 Million | $633.00 Million | ▼ -175.9% |
| 2022 | 0.64x | $438.00 Million | $688.00 Million | ▲ +286.5% |
| 2021 | -0.34x | $-256.17 Million | $750.45 Million | ▼ -182.9% |
| 2020 | 0.41x | $111.17 Million | $269.99 Million | ▲ +122.0% |
| 2019 | -1.87x | $-73.46 Million | $39.27 Million | ▼ -74.0% |
| 2018 | -1.08x | $-43.00 Million | $39.98 Million | ▼ -57.1% |
| 2017 | -0.68x | $-25.06 Million | $36.62 Million | ▲ +45.9% |
| 2016 | -1.26x | $-12.94 Million | $10.24 Million | — |